I, too, thank Foysol Choudhury for bringing the motion to the Parliament. He has reminded us clearly of the daily challenges that people who are living with diabetes face and how technology can transform their lives.
I thank colleagues across the chamber for their contributions and for sharing their experiences of living with diabetes or supporting people who do. I always think that it is helpful when someone who does not live with diabetes shares their experiences, so I thank Brian Whittle for that.
It has been a very informative debate, and I have been heartened to hear that members across the chamber recognise the importance of expanding access to diabetes technology. I thank all those who have travelled here tonight, those who are watching and those who have generously shared their stories with me and colleagues. I also thank Carol Mochan for raising the importance of not forgetting about inequalities and for setting out how diabetes can impact on different areas of Scotland.
It remains the Scottish Government’s ambition to make diabetes technology available to everyone in Scotland who would benefit from it. The Scottish Government has committed to doing that for all children and young people, as well as to working towards universal access for adults. I regularly hear from people who are living with diabetes about the importance of continuing to work towards making the technology available to all.
I would like to reflect briefly on where things were just one year ago. Many members told me of the considerable waiting lists that constituents were facing and that many of them had a sense of hopelessness about the lack of protected funding. Miles Briggs, Foysol Choudhury and Sarah Boyack all talked about the situation in NHS Lothian. I am aware of that situation and I am pleased that my officials are working very closely with NHS Lothian. We discuss that issue a lot.
I recognise that there is more to do, and I am under no illusion that the job is complete. Before I touch on some of the key issues that have been raised, I would like to outline the significant progress that we have made since last year. However, before I do that, I thank the local services and give them credit for their unwavering commitment to the programme. The process has been no mean feat, so I highlight the work that each and every diabetes team has had to put into it. As Emma Harper did, I also thank the staff for the non-judgmental support that they provide to people who are living with diabetes.
This year, we entered a new phase of delivery by establishing a national programme. The primary aim of it was to remove the postcode-lottery elements of care that many people were experiencing. The programme began in May last year, with an initial investment to support 2,100 individuals to receive an insulin pump or a continuous glucose monitor, or both, and to create a hybrid closed-loop system. That was on top of the £29 million that we have invested in diabetes tech since 2016.
The initial focus of the programme has been to provide a closed-loop system to all children and young people who want it. As it stands, 64 per cent of children who are living with type 1 diabetes have access to a closed-loop system, and we expect the figure to be around 80 per cent by the end of this financial year. Some health boards have already exceeded that target. We know that access for young people in Scotland is catching up with the situation in the rest of the world. I reiterate how life changing that will be for many families, which Christine Grahame spoke about.
One reason why we have been able to do that at pace is that we commissioned a new national onboarding service. That team is comprised of highly experienced diabetes clinicians and, whih is most important, peer-support staff, who all help people to learn to navigate living with their new normal, which is their living with a closed-loop system.
Although I am proud to outline to members the significant progress, I also recognise the challenges that remain for many people. As others have said, more than 35,000 people are living with type 1 diabetes in Scotland, and demand for diabetes tech currently outstrips the capacity in the system.
I will respond to Annie Wells’s concerns about brand choice for children. I am aware that there is growing concern that children cannot access the most appropriate technology for their needs, but I reiterate that the national programme has provided adequate funding to allow all local services to provide any of the CGM brands that are available on the market. However, it is important to note that a prescribing clinician might feel that they can maximise access to the kits, while providing safe and effective care, by using more cost-efficient brands. I cannot discuss the cost details, but there are significant differences. Our clinicians may offer a lower-priced brand to allow more of their patients to access the technology, although individuals and families should continue to have conversations with their clinician team. I again reassure members that the national programme is committed to supporting brand choice for children and young people.
Mr Choudhury and others asked about the plan. Although other nations have published strategies and targets, we were fortunate in Scotland to be able to kick-start a significant roll-out programme as soon as funds were released. We have also found that negotiating with suppliers to secure bulk national deals has allowed us to secure the best deals; setting targets for the numbers might have prevented us from achieving the current prices.
We are also able to work with officials to secure appropriate investment year on year and to ensure that it reaches as many people as possible. I reassure members that, although we do not have a formal publication, we are rolling out at pace, which is, I am sure, what matters to most people who are living with diabetes.
Brian Whittle’s comments allow me to talk about the preventative side and the work that we are doing on the population health framework with the Convention of Scottish Local Authorities and in collaboration with Public Health Scotland, directors of public health and key local, regional and national partners. I look forward to working closely with Mr Whittle and others on a clear focus on prevention of type 2 diabetes. I completely understand that different approaches are required for people living with type 1.